{"id":2920,"date":"2019-04-25T14:30:00","date_gmt":"2019-04-25T14:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/"},"modified":"2019-04-25T14:30:00","modified_gmt":"2019-04-25T14:30:00","slug":"kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/","title":{"rendered":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)"},"content":{"rendered":"

P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 25 april 2019 beslutades bl.a. f\u00f6ljande:<\/span><\/p>\n

\u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 201<\/span>8<\/span>.<\/span><\/p>\n

\u2022 Val av G\u00f6sta Johannesson (omval), Camilla \u00d6berg (omval), Folke Nilsson (omval), Yvonne M\u00e5rtensson (omval), Alan Raffensperger (omval) och Dag Andersson till styrelseledam\u00f6ter, samt val av G\u00f6sta Johannesson till styrelsens ordf\u00f6rande, i enlighet med valberedningens f\u00f6rslag.<\/span><\/p>\n

\u2022 Styrelsearvode ska utg\u00e5 med totalt 1 180 000 kronor, varav 250 000 kronor till styrelseordf\u00f6randen, 150 000 kronor vardera till \u00f6vriga styrelseledam\u00f6ter, 40 000 kronor till ordf\u00f6rande i revisionsutskottet, 40 000 kronor till ordf\u00f6rande i ers\u00e4ttningsutskottet samt 25 000 kronor till envar av \u00f6vriga ledam\u00f6ter i dessa utskott.
<\/span><\/p>\n

\u2022 F\u00f6reslagna principer f\u00f6r ers\u00e4ttning och andra anst\u00e4llningsvillkor f\u00f6r bolagsledningen godk\u00e4ndes.<\/span><\/p>\n

\u2022 Styrelsen bemyndigades att f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma vid ett eller flera tillf\u00e4llen besluta om<\/span><\/p>\n

nyemission av h\u00f6gst 2 640\u00a0000 aktier motsvarande knappt 10 procent av det totala antalet aktier och r\u00f6ster i bolaget.<\/span><\/p>\n

\u2022 F\u00f6reslagen emission av totalt 351\u00a0000 teckningsoptioner i enlighet med f\u00f6reslaget teckningsoptionsprogram godk\u00e4ndes. Teckningsoptionerna ska erbjudas till samtliga av XVIVO Perfusion-koncernen anst\u00e4llda den 1 maj 2019 samt nyanst\u00e4llda d\u00e4refter med anst\u00e4llningsdatum senast den 18 oktober 2019 till en kurs motsvarande marknadsv\u00e4rdet vid utgivandetillf\u00e4llet. Teckning av aktier med st\u00f6d av teckningsoptionerna kan ske under perioden fr\u00e5n och med den 3 maj 2021 till och med 31 maj 2021. En teckningsoption ber\u00e4ttigar till teckning av en ny aktie i bolaget. Vid fullt utnyttjande av optionsr\u00e4tterna kommer aktiekapitalet att \u00f6ka med 9 126 kronor motsvarande en utsp\u00e4dning om cirka 1,33 procent av det totala antalet aktier och r\u00f6ster i bolaget. <\/span><\/p>\n

\u2022 Styrelsen bemyndigandes att f\u00f6r tiden intill n\u00e4sta \u00e5rsst\u00e4mma, vid ett eller flera tillf\u00e4llen fatta beslut om att f\u00f6rv\u00e4rva h\u00f6gst s\u00e5 m\u00e5nga aktier i XVIVO Perfusion AB att innehavet vid var tid inte \u00f6verstiger en tiondel av samtliga aktier i bolaget.<\/span><\/p>\n

G\u00f6teborg 25 april 2019<\/span><\/p>\n

XVIVO Perfusion AB (publ)<\/span><\/p>\n

Styrelsen<\/span><\/p>\n

\n

F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/span><\/p>\n

G\u00f6sta Johannesson, styrelsens ordf\u00f6rande, telefon +46 8-614 00 20<\/span><\/p>\n

Christoffer Rosenblad, CFO, telefon +46\u00a0735-19 21 59, e-post: christoffer.rosenblad@xvivoperfusion.com<\/a><\/span><\/p>\n

Magnus Nilsson, VD, +46 31-788 21 50, e-post: magnus.nilsson@xvivoperfusion.com<\/a><\/span><\/p>\n

F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/a>.<\/span><\/p>\n

Denna information \u00e4r s\u00e5dan information som XVIVO Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning och lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 25 april 2019 kl. 16.30 CET.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 25 april 2019 beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2018. \u2022 Val…<\/p>\n","protected":false},"template":"","class_list":["post-2920","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-info"],"acf":[],"yoast_head":"\nKommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 25 april 2019 beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2018. \u2022 Val...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\\\/\",\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2019-04-25T14:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/","og_locale":"en_US","og_type":"article","og_title":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","og_description":"P\u00e5 XVIVO Perfusions \u00e5rsst\u00e4mma den 25 april 2019 beslutades bl.a. f\u00f6ljande: \u2022 Ingen utdelning l\u00e4mnas f\u00f6r verksamhets\u00e5ret 2018. \u2022 Val...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/","name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2019-04-25T14:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/kommunike-fran-arsstamma-i-xvivo-perfusion-ab-publ-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Kommunik\u00e9 fr\u00e5n \u00e5rsst\u00e4mma i XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}